| Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net income | 1,351 | 917 | 1,023 | 864 |
|---|
| Depreciation | 92 | 96 | 120 | 132 |
|---|
| Amortization | 103 | 116 | 116 | 145 |
|---|
| Impairment of assets | 7 | 9 | - | - |
|---|
| Acquired in-process research and development and milestones | - | - | 8 | 81 |
|---|
| Contingent consideration | - | - | - | 11 |
|---|
| Deferred income tax benefit | -288 | -18 | -485 | -160 |
|---|
| Stock-based compensation | 59 | 75 | 101 | 105 |
|---|
| Unrealized foreign exchange (gain) loss | - | 18 | -40 | 2 |
|---|
| Other | -12 | -26 | -31 | -41 |
|---|
| Accounts receivable | 277 | 123 | 212 | -383 |
|---|
| Inventories | 138 | 220 | 230 | 131 |
|---|
| Other current assets | -353 | 43 | 10 | 236 |
|---|
| Trade accounts payable | 663 | -237 | 163 | -157 |
|---|
| Accrued and other current liabilities | 329 | 172 | 102 | -101 |
|---|
| Income taxes payable | -119 | 7 | 16 | -65 |
|---|
| Other | -55 | 8 | -16 | -29 |
|---|
| Net Cash Flows Provided by Operating Activities | - | - | - | 939 |
|---|
| Capital expenditures | 192 | 196 | 251 | 175 |
|---|
| Proceeds from sale of property, plant and equipment | 7 | 7 | 1 | 4 |
|---|
| Acquired in-process research and development and milestones | 104 | 107 | 8 | 71 |
|---|
| Dermavant acquisition, net of cash acquired | - | - | - | 166 |
|---|
| Purchase of product rights and asset acquisition | 192 | 124 | 2 | 105 |
|---|
| Net Cash Flows Used in Investing Activities | - | - | - | -513 |
|---|
| Proceeds from debt | 9,470 | - | 80 | 1,186 |
|---|
| Repayments of debt | 112 | 108 | 338 | 1,197 |
|---|
| Payment of long-term debt issuance costs | 118 | - | - | 38 |
|---|
| Net transfers to Merck & Co., Inc. | -440 | 24 | - | - |
|---|
| Employee withholding taxes related to stock-based awards | - | 11 | 17 | 22 |
|---|
| Dividend payments | 145 | 290 | 294 | 297 |
|---|
| Net Cash Flows Used in Financing Activities | - | - | - | -368 |
|---|
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 23 | -36 | 17 | -76 |
|---|
| Net Decrease in Cash and Cash Equivalents | 667 | -31 | -13 | -18 |
|---|